We will develop first-in-class catalytic antibodies (Catabodies) and electrophilic vaccines (E-vaccines) for a range of unmet medical needs.
We are committed to commercializing our technology platform by targeting defined disease-associated proteins to solve the unmet needs, including the needs of economically disadvantaged patients.
We will achieve our mission by applying the Catabody and E-Vaccine technologies, which generates multiple products for treating and preventing life-threatening diseases.
Our lead catabodies focus on healthy aging and age-associated diseases. Our lead E-vaccine has promise for effective prophylaxis and therapy of HIV infection worldwide.
Our lead products reflect the potential of the technology platform to generate solutions to major public health challenges.